TILT 321
Alternative Names: TILT-321Latest Information Update: 03 Nov 2023
At a glance
- Originator TILT Biotherapeutics
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 Oct 2023 TILT Biotherapeutics has patent protection for local delivery of bispecific antibody(TILT Biotherapeutics webiste, October 2023)
- 26 Oct 2023 Early research in Solid tumours in Finland (Parenteral) (TILT Biotherapeutics webiste, October 2023)
- 26 Oct 2023 Early research in Solid tumours in USA (Parenteral) (TILT Biotherapeutics webiste, October 2023)